Celgene (CELG) : ABRAXANE therapy for advanced pancreatic cancer

Celgene: Analyses of MPACT Trial evaluating ABRAXANE combination therapy for the treatment of advanced pancreatic cancer presented at ASCO 2013 (CELG) 119.65 -4.00 : Co announced several analyses of a phase III clinical trial of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in previously untreated patients with advanced pancreatic cancer. The data were presented at the American Society of Clinical Oncology (ASCO) 2013 annual meeting in Chicago. The MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) overall trial results demonstrated that patients treated with ABRAXANE plus gemcitabine had a statistically significant improvement in overall survival compared with those treated with gemcitabine alone.

** daily **

 ** weekly **